Researchers find key to stopping cancer in its tracks

Jan 09, 2008

University of Manchester researchers have discovered a key process that may be involved in the spread of cancer by studying the growth of human embryonic stem (ES) cells.

Dr Chris Ward and his team used the ES cells to investigate how some tumours are able to migrate to other parts of the body, which makes the treatment of cancer much more difficult. He believes his work could lead to new treatments and stop 80-90% of cancers in their tracks.

They studied a crucial change that makes cancer cells able to start moving and spread into other tissues.

Normal cells, as well as early cancer cells, are called epithelial cells because they bind tightly to each other forming stable layers of tissue. However, as a tumour becomes more advanced some of the cells change to become 'mesenchymal'. Mesenchymal cells do not bind to each other, forming more disorganised tissues in which the cells can move around. Since this crucial change - known as the epithelial-mesenchymal transition - was first observed in the early embryo, Dr Ward theorised that embryonic stem cells might undergo a similar process.

The study, which was funded by the Association for International Cancer Research (AICR) and also involved the University's immunology group at the Paterson Institute for Cancer Research (PICR), found that the protein E-cadherin stopped cells from migrating during normal growth.

It also found that, as well as helping cells stick together, E-cadherin also blocked the action of another protein known to increase the mobility of cells. This important dual function of E-cadherin opens up the potential for new targets to prevent tumour cells from spreading.

Dr Ward, whose findings are published in the journal Cancer Research, said: "We have shown that ES cells spontaneously change in a manner that is remarkably similar to the epithelial-mesenchymal transition. They lose the proteins that cells use to bind to each other and have other protein alterations that are characteristic of spreading cancer cells.

"Since ES cells can be grown in the laboratory, where they keep the characteristics of the cells in the early embryo, they can be studied in detail. By studying these ES cells we have already identified a novel component of this transition process. We expect the use of ES cells will lead to the identification of other unknown factors involved in cancer cell spread, hopefully leading to new avenues for cancer therapy."

Previously, it has not been possible to study this crucial transition in patients since this would involve invasive techniques that may interfere with any treatment of the disease. Where excised tumour cells have been used, it is difficult to know if the cells were from the right area - i.e. the growing part of the tumour. The team's discovery that it happens spontaneously in ES cells means that it can be studied much more easily in the laboratory.

"Understanding how cancer cells start to spread is tremendously important for cancer research; tumours that do not spread are rarely dangerous," said Dr Ward, who leads the stem cell research group in the School of Dentistry.

"It is the ability of tumours to invade into other tissues and spread around the body that makes them so dangerous. Finding out more about the mechanism that controls the spread of cancer cells will help us find new treatments that can prevent tumours spreading and make them essentially harmless."

He added: "Previously we studied the process in mouse ES cells. When we used human ES cells, we found they had a similar response, which is very good news.

"Potentially, our findings can be applied to the most common form of cancer, carcinoma, found in the breast, lung and gut for example, which makes up 80-90% of all cancers."

Norman Barrett, Chief Executive of AICR, said: "The grant to support Dr Ward's work is given in line with the charity's policy of funding the most exciting and novel approaches to research worldwide. It is important to fund work that pushes the boundaries and Dr Ward and his team are pursuing research which could in future change the lives of tens of thousands of people in the UK and many more across the world."

Source: University of Manchester

Explore further: Pembrolizumab shows real promise against head and neck cancer

Related Stories

New insight into lethal fungus infection in wildlife

May 21, 2015

The introduction of a lethal fungus infection that could threaten the UK's amphibian populations has not been caused by exposure to infected colonies of African clawed frogs, according to new research from ...

A turning point in the physics of blood

May 07, 2015

Mike Graham knows that fluid dynamics can reveal much about how the flow of blood helps and hinders individual blood cells as they go about their work.

Lightbulb using graphene is to go on sale this year

Mar 30, 2015

The BBC reported on Saturday that a graphene bulb is set for shops, to go on sale this year. UK developers said their graphene bulb will be the first commercially viable consumer product using the super- ...

In the sea, a deadly form of leukemia is catching

Apr 09, 2015

Outbreaks of leukemia that have devastated some populations of soft-shell clams along the east coast of North America for decades can be explained by the spread of cancerous tumor cells from one clam to another. ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.